Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Brushes Aside Roche's Extended Takeover Bid

NEW YORK (GenomeWeb News) — Roche yesterday said it has extended its tender offer deadline to buy Ventana Medical Systems to the close of business on Aug. 23.
 
Roche's original deadline lapsed last night, and the federal anti-trust waiting period passed earlier this week.
  
In response, Ventana reiterated that the offer remains “wholly inadequate” and that it is “significantly below our current market price.”
 
The offer “does not even come close to reflecting the intrinsic value of the company, its strong growth prospects in an accelerating market, and the synergy value of Ventana to Roche,” Ventana said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.